2021/10/26 更新

写真a

モリヤマ マサト
森山 雅人
MORIYAMA Masato
所属
教育研究院 医歯学系 医学系列 准教授
医学部 医学科 准教授
医歯学総合研究科 分子細胞医学専攻 遺伝子制御 准教授
職名
准教授
▶ researchmapのプロフィールを表示
外部リンク

学位

  • 医学博士 ( 2009年3月   新潟大学 )

研究分野

  • ライフサイエンス / 医化学  / 再生医学

  • ライフサイエンス / 病態医化学  / 分子腫瘍学

  • ライフサイエンス / 薬系化学、創薬科学  / 医薬分子機能学

  • ライフサイエンス / 血液、腫瘍内科学  / 血栓止血学

  • その他 / その他  / 腫瘍検査医学 病態検査学

経歴(researchmap)

  • 新潟大学大学院医歯学総合研究科   腫瘍内科学分野   准教授

    2015年9月 - 現在

      詳細を見る

  • 新潟大学医歯学総合病院   腫瘍センター   がん相談支援センター長

    2013年5月 - 現在

      詳細を見る

  • 新潟大学大学院医歯学総合研究科   腫瘍内科学分野   助教

    2013年4月 - 2015年8月

      詳細を見る

  • 新潟大学医歯学総合病院   腫瘍センター   特任助教

    2012年10月 - 2013年3月

      詳細を見る

  • 新潟大学医歯学総合病院   医師キャリア支援センター   特任助教

    2008年11月 - 2013年3月

      詳細を見る

経歴

  • 新潟大学   医学部 医学科   准教授

    2015年9月 - 現在

  • 新潟大学   医歯学総合研究科 分子細胞医学専攻 遺伝子制御   准教授

    2015年9月 - 現在

  • 新潟大学   医学部 医学科   助教

    2013年4月 - 2015年8月

  • 新潟大学   医歯学総合研究科 分子細胞医学専攻 遺伝子制御   助教

    2013年4月 - 2015年8月

  • 新潟大学   医歯学総合病院 医師キャリア支援センター   特任助教

    2008年11月 - 2013年3月

学歴

  • 新潟大学大学院   医歯学総合研究科   生体機能調整医学専攻

    - 2009年3月

      詳細を見る

  • 自治医科大学   医学部

    - 1994年3月

      詳細を見る

所属学協会

▶ 全件表示

委員歴

  • 日本検査血液学会   評議員  

      詳細を見る

  • 日本検査血液学会   血栓止血検査標準化委員  

      詳細を見る

  • 日本血栓止血学会   代議員  

      詳細を見る

    団体区分:学協会

    researchmap

  • 日本抗リン脂質抗体標準化WS   幹事  

      詳細を見る

    団体区分:その他

    researchmap

  • 新潟県・新潟市合同精度管理専門委員会   専門委員  

      詳細を見る

    団体区分:自治体

    researchmap

取得資格

  • 医師

 

論文

  • Analysis of Pharmacokinetics in the Cochlea of the Inner Ear

    Seishiro Sawamura, Genki Ogata, Kai Asai, Olga Razvina, Takeru Ota, Qi Zhang, Sasya Madhurantakam, Koei Akiyama, Daisuke Ino, Sho Kanzaki, Takuro Saiki, Yoshifumi Matsumoto, Masato Moriyama, Yasuo Saijo, Arata Horii, Yasuaki Einaga, Hiroshi Hibino

    Frontiers in Pharmacology   12   2021年5月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Frontiers Media SA  

    Hearing loss affects >5% of the global population and therefore, has a great social and clinical impact. Sensorineural hearing loss, which can be caused by different factors, such as acoustic trauma, aging, and administration of certain classes of drugs, stems primarily from a dysfunction of the cochlea in the inner ear. Few therapeutic strategies against sensorineural hearing loss are available. To develop effective treatments for this disease, it is crucial to precisely determine the behavior of ototoxic and therapeutic agents in the microenvironment of the cochlea in live animals. Since the 1980s, a number of studies have addressed this issue by different methodologies. However, there is much less information on pharmacokinetics in the cochlea than that in other organs; the delay in ontological pharmacology is likely due to technical difficulties with accessing the cochlea, a tiny organ that is encased with a bony wall and has a fine and complicated internal structure. In this review, we not only summarize the observations and insights obtained in classic and recent studies on pharmacokinetics in the cochlea but also describe relevant analytical techniques, with their strengths, limitations, and prospects.

    DOI: 10.3389/fphar.2021.633505

    researchmap

  • Analysis of Pharmacokinetics in the Cochlea of the Inner Ear. 国際誌

    Seishiro Sawamura, Genki Ogata, Kai Asai, Olga Razvina, Takeru Ota, Qi Zhang, Sasya Madhurantakam, Koei Akiyama, Daisuke Ino, Sho Kanzaki, Takuro Saiki, Yoshifumi Matsumoto, Masato Moriyama, Yasuo Saijo, Arata Horii, Yasuaki Einaga, Hiroshi Hibino

    Frontiers in pharmacology   12   633505 - 633505   2021年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Hearing loss affects >5% of the global population and therefore, has a great social and clinical impact. Sensorineural hearing loss, which can be caused by different factors, such as acoustic trauma, aging, and administration of certain classes of drugs, stems primarily from a dysfunction of the cochlea in the inner ear. Few therapeutic strategies against sensorineural hearing loss are available. To develop effective treatments for this disease, it is crucial to precisely determine the behavior of ototoxic and therapeutic agents in the microenvironment of the cochlea in live animals. Since the 1980s, a number of studies have addressed this issue by different methodologies. However, there is much less information on pharmacokinetics in the cochlea than that in other organs; the delay in ontological pharmacology is likely due to technical difficulties with accessing the cochlea, a tiny organ that is encased with a bony wall and has a fine and complicated internal structure. In this review, we not only summarize the observations and insights obtained in classic and recent studies on pharmacokinetics in the cochlea but also describe relevant analytical techniques, with their strengths, limitations, and prospects.

    DOI: 10.3389/fphar.2021.633505

    PubMed

    researchmap

  • Age-Based Comparison of Hematological Toxicity in Patients with Lung Cancer

    Yuki Sakai, Qiliang Zhou, Yoshifumi Matsumoto, Takuro Saiki, Masato Moriyama, Akira Toyama, Yasuo Saijo

    Oncology   1 - 8   2020年8月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:S. Karger AG  

    DOI: 10.1159/000507864

    researchmap

  • 血液凝固線溶検査における検体の遠心条件および保存条件の影響

    松田 将門, 小宮山 豊, 鈴木 健史, 森山 雅人

    日本検査血液学会雑誌   21 ( 2 )   136 - 144   2020年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本検査血液学会  

    【目的】凝固検査検体取扱いに関するコンセンサスでは示されていない分子マーカー検査や容量の大きい採血管を用いた凝固時間検査に適切な検体の遠心条件を調べる。【方法】13名の被験者を対象に実験1では一人につき2mL、実験2では一人につき5mLの検体を3本調製した。実験1では20℃の下、3通りの条件(1,500×gで15分、2,000×gで10分、3,500×gで6分)で検体を遠心し、血漿中残存血小板数、トロンビン-アンチトロンビン複合体(TAT)、フィブリンモノマー複合体、フィブリノゲン・フィブリン分解産物、Dダイマーを測定した。実験2では1,500×gで20℃の下、3通りの時間(10分、15分、20分)で検体を遠心し、血漿中残存血小板数を測定した。また、各遠心時間の検体を遠心直後および凍結融解後に希釈ラッセル蛇毒時間(dRVVT)を測定した。【結果】実験1ではどの条件でも残存血小板数は10×10^9/L未満であったが、遠心力上昇に伴いTATが有意に高値を示した。実験2では残存血小板数を10×10^9/L未満にするには20分以上遠心が必要であり、残存血小板数10×10^9/L以上の検体では凍結融解後のdRVVTが偽短縮した。【結論】分子マーカー検査、凝固時間検査ともに遠心力は1,500×gが推奨され、2mL採血管では15分以上、5mL採血管では20分以上の遠心が必要と考えられた。(著者抄録)

    researchmap

  • 古くて新しい希釈プロトロンビン時間測定 本邦の特徴を活用したループスアンチコアグラント検出に最適な検査手順確立と臨床応用

    松田 将門, 小宮山 豊, 家子 正裕, 内藤 澄悦, 吉田 美香, 星山 良樹, 成田 一衛, 森山 雅人

    日本検査血液学会雑誌   21 ( 学術集会 )   S209 - S209   2020年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本検査血液学会  

    researchmap

  • ベセスダ力価と対応したFVIII-binding IgMの動態 インヒビター発生前後の先天性血友病Aでの経験

    松田 将門, 小宮山 豊, 野上 恵嗣, 古川 晶子, 西條 康夫, 森山 雅人

    日本血栓止血学会誌   31 ( 2 )   266 - 266   2020年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本血栓止血学会  

    researchmap

  • Treatment of Gastric and Gastroesophageal Cancer Patients with Hemodialysis by CapeOX. 査読

    Sasaki K, Zhou Q, Matsumoto Y, Saiki T, Moriyama M, Saijo Y

    Internal medicine (Tokyo, Japan)   58 ( 19 )   2791 - 2795   2019年10月

  • Treatments and outcomes of older patients with esophageal cancer: Comparison with younger patients. 査読

    Matsumoto Y, Kimura K, Zhou Q, Sasaki K, Saiki T, Moriyama M, Saijo Y

    Molecular and clinical oncology   11 ( 4 )   383 - 389   2019年10月

  • 骨髄異形成症候群と低悪性度B細胞リンパ腫を合併し、多彩な合併症を呈した1例

    海發 茜, 小堺 貴司, 田村 秀, 片桐 隆幸, 河本 啓介, 難波 亜矢子, 布施 香子, 牛木 隆志, 柴崎 康彦, 森山 雅人, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   60 ( 10 )   1503 - 1503   2019年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本血液学会-東京事務局  

    researchmap

  • Cancers among adolescents and young adults at one institution in Japan. 査読

    Kamimura K, Matsumoto Y, Zhou Q, Moriyama M, Saijo Y

    Oncology letters   16 ( 6 )   7212 - 7222   2018年12月

  • Trachea Engineering Using a Centrifugation Method and Mouse-Induced Pluripotent Stem Cells. 査読

    Zhou Q, Ye X, Ran Q, Kitahara A, Matsumoto Y, Moriyama M, Ajioka Y, Saijo Y

    Tissue engineering. Part C, Methods   24 ( 9 )   524 - 533   2018年9月

  • The Prognostic Nutrition Index Predicts the Development of Hematological Toxicities in and the Prognosis of Esophageal Cancer Patients Treated with Cisplatin Plus 5-Fluorouracil Chemotherapy 査読

    Yoshifumi Matsumoto, Qiliang Zhou, Kensuke Kamimura, Masato Moriyama, Yasuo Saijo

    Nutrition and Cancer   70 ( 3 )   447 - 452   2018年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Routledge  

    The prognostic nutrition index (PNI), calculated based on serum albumin and lymphocyte counts, predicts the prognosis of several cancers, including operated esophageal cancers. In this study, we determined whether PNI could predict the occurrence of severe adverse events by chemotherapy and chemoradiotherapy, and overall survival in esophageal cancer. We collected data from 191 patients with esophageal cancer treated with at least one course of cisplatin and 5-fluorouracil from 2005 to 2016. We compared the incidences of severe adverse events and overall survival between a high- and a low-PNI group. The optimal cut-off value of the Onodera PNI was 43.2. Patients with low PNIs suffered more frequent severe adverse events than did those with high PNIs, and the latter patients survived longer. The PNI was independently prognostic of overall survival and stage. The PNI predicted the development of severe adverse events caused by chemotherapy or chemoradiotherapy, and overall survival, in esophageal cancer patients.

    DOI: 10.1080/01635581.2018.1445765

    Scopus

    PubMed

    researchmap

  • [Myelodysplastic syndrome with refractory hemorrhage due to reduced platelet aggregation activity]. 査読

    Tanaka T, Kozakai T, Kitajima T, Fuse K, Kobayashi H, Ushiki T, Shibazaki Y, Moriyama M, Takizawa J, Sone H, Fuse I, Masuko M

    [Rinsho ketsueki] The Japanese journal of clinical hematology   58 ( 12 )   2402 - 2405   2017年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本血液学会  

    <p>症例は75歳の女性。血液検査で貧血と末梢血に芽球を認められたため,当院を紹介受診した。骨髄穿刺で骨髄異形成症候群(myelodysplastic syndrome with excess blasts 2, MDS-EB-2)と診断された。血球減少の進行や芽球の増加,および出血症状はなく経過していた。診断から10ヶ月後,左手母指球に外傷を負い,内出血が持続し,止血困難となったため緊急入院した。血小板数は正常範囲であったが,血小板機能検査でコラーゲン凝集能とアラキドン酸凝集能の低下を認められた。抗血小板薬の内服はなく,またこれまで出血傾向の既往もなかったことから,MDSによる2次性の血小板機能低下による出血と判断し,血小板輸血を行い止血した。MDSの患者では,潜在的に血小板凝集能が低下していることが多く,血小板数の割に出血傾向が強い場合には血小板凝集能を調べ,血小板輸血などの治療介入を検討する必要がある。</p>

    DOI: 10.11406/rinketsu.58.2402

    PubMed

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2018121562

  • Peripheral T-cell lymphoma, not otherwise specified: a retrospective single-center analysis. 査読

    Suzuki T, Kawamoto K, Tamura S, Uemura S, Kaihatsu A, Nemoto H, Kobayashi H, Ushiki T, Fuse K, Shibazaki Y, Moriyama M, Masuko M, Narita M, Sone H, Aoki S, Nakamura N, Oshima K, Takizawa J

    [Rinsho ketsueki] The Japanese journal of clinical hematology   58 ( 8 )   905 - 911   2017年

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.11406/rinketsu.58.905

    PubMed

    researchmap

  • Successful umbilical cord blood hematopoietic stem cell transplantation in a patient with adult T-cell leukemia/lymphoma initially achieving complete remission with anti-CC chemokine receptor 4 antibody combined chemotherapy. 査読

    Suwabe T, Shibasaki Y, Kaihatsu A, Katagiri T, Miyakoshi S, Fuse K, Kobayashi H, Ushiki T, Moriyama M, Takizawa J, Narita M, Sone H, Masuko M

    [Rinsho ketsueki] The Japanese journal of clinical hematology   58 ( 1 )   32 - 36   2017年

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.11406/rinketsu.58.32

    PubMed

    researchmap

  • Inhibition of Glutaminolysis Inhibits Cell Growth via Down-regulating Mtorc1 Signaling in Lung Squamous Cell Carcinoma 査読

    Xulu Ye, Qiliang Zhou, Yoshifumi Matsumoto, Masato Moriyama, Shun Kageyama, Masaaki Komatsu, Seijiro Satoh, Masanori Tsuchida, Yasuo Saijo

    ANTICANCER RESEARCH   36 ( 11 )   6021 - 6029   2016年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:INT INST ANTICANCER RESEARCH  

    Background/Aim: Inhibition of glutaminolysis has been reported as a promising therapeutic strategy to target several solid carcinomas. We aimed to investigate the effects of glutaminolysis on cell proliferation in lung squamous cell carcinoma cell lines and to explore the potential of targeting glutaminolysis as an anticancer strategy. Materials and Methods: Glutamine (Gln) dependence was assessed in six lung squamous cell carcinoma cell lines. Cell proliferation, mammalian target of rapamycin complex 1 (mTORC1) activity and the induction of autophagy were assessed after inhibition of glutaminolysis via Gln depletion or glutaminase (GLS) inhibition. Results: Five of six lung squamous cell carcinoma cell lines exhibited glutamine- dependence. The extent of dependence was correlated with the mRNA levels of GLS1/GLS2. Inhibition of glutaminolysis inhibited cell proliferation by down-regulating of mTORC1 signaling and inducing autophagy in Gln-dependent lung squamous cell carcinoma cell lines. Conclusion: Targeting glutaminolysis may represent a potential therapeutic strategy for the treatment of Gln-dependent lung squamous cell carcinomas.

    DOI: 10.21873/anticanres.11191

    Web of Science

    PubMed

    researchmap

  • Chromosomal rearrangements in myoepithelial carcinoma of the breast that presented as metachronic double cancer with invasive ductal carcinoma in the ipsilateral breast 査読

    Hiroyuki Kawashima, Takashi Ariizumi, Yasuo Saijo, Masato Moriyama, Hajime Umezu, Yoshiyuki Ikeda, Akira Ogose, Naoto Endo

    CANCER GENETICS   209 ( 11 )   501 - 505   2016年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCIENCE INC  

    Myoepithelial carcinoma of the breast is an extremely rare tumor composed entirely of malignant spindle cells with myoepithelial differentiation. The majority of previously reported cases have mainly described the clinicopathological features of the disease, and few have presented cytogenetic data. We herein present the case of a 48-year-old woman who was admitted with a left sided breast lump in the inner upper quadrant that was initially diagnosed as a myoepithelioma with potentially malignant disorder. At 12 months after resection, she complained about a newly developed solid mass in the subareolar region of the ipsilateral breast that was diagnosed as an invasive ductal carcinoma. In addition, 16 months after the initial admission, a re-growing remnant lesion recurred in the inner upper quadrant and was ultimately diagnosed as a myoepithelial carcinoma. Lymph node metastasis of the myoepithelial carcinoma was also observed in her left axillary region 11 months after local recurrence. A cytogenetic analysis showed recurring specific chromosomal alterations both in the locally recurrent and in the lymph-node metastatic lesion: 48, XX, t(5;18)(q13;q23),del(6)(q?),+14. + marl. To our knowledge, this is the first published report of clonal chromosomal rearrangements in myoepithelial carcinoma of the breast that presented as metachronic double cancer with invasive ductal carcinoma in the ipsilateral breast.

    DOI: 10.1016/j.cancergen.2016.10.005

    Web of Science

    PubMed

    researchmap

  • Myelosuppression by chemotherapy in obese patients with gynecological cancers 査読

    Kensuke Kamimura, Yoshifumi Matsumoto, Qiliang Zhou, Masato Moriyama, Yasuo Saijo

    CANCER CHEMOTHERAPY AND PHARMACOLOGY   78 ( 3 )   633 - 641   2016年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER  

    The American Society of Clinical Oncology provides clinical practice guidelines for appropriate cytotoxic chemotherapy dosing for obese adult patients with cancer. The panel recommends that actual body weight should be used when selecting cytotoxic chemotherapy doses regardless of obesity status. However, there have been no reports regarding the appropriate cytotoxic chemotherapy dosing for obese Japanese patients with cancer.
    We collected data from 216 gynecological cancer patients who were treated with at least one course of a paclitaxel and carboplatin (TC) regimen or a docetaxel and carboplatin (DC) regimen at Niigata University Medical and Dental Hospital from July 2006 to April 2014. Patients were divided into three groups according to body mass index (BMI): obese (BMI aeyen 25), normal (BMI 18.5-24.9), and underweight (BMI &lt; 18.5), as defined by the Japan Society for the Study of Obesity. We analyzed hematological toxicities by full weight-based chemotherapy in each group.
    The rates of grade 3/4 leukocytopenia, neutropenia, and thrombocytopenia were not significantly different among the three BMI groups on all patient analyses. For the TC regimen, the obese and normal groups had significantly lower leukocytopenia (grade 3/4) rates than did the underweight group. Also, significant positive correlations between BMI and the nadirs of leukocytes, neutrophils, platelets, and hemoglobin were observed. For the DC regimen, no significant difference was observed among the BMI groups and the rate of grade 3/4 hematological toxicities.
    We did not observe stronger myelosuppression in obese cancer patients compared with non-obese cancer patients. Therefore, the cytotoxic chemotherapy dose should be calculated by the actual body weight and unnecessary dose reduction should be avoided.

    DOI: 10.1007/s00280-016-3119-2

    Web of Science

    PubMed

    researchmap

  • Relationship between HMGB1 and PAI-1 after allogeneic hematopoietic stem cell transplantation 査読

    Shosaku Nomura, Yoshinobu Maeda, Kazuyoshi Ishii, Yuta Katayama, Hideo Yagi, Naoto Fujishima, Shuichi Ota, Masato Moriyama, Takayuki Ikezoe, Yasuhiko Miyazaki, Kunio Hayashi, Shinya Fujita, Atsushi Satake, Tomoki Ito, Taiichi Kyo, Mitsune Tanimoto

    Journal of Blood Medicine   7   1 - 4   2016年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Dove Medical Press Ltd  

    Background: Conditioning regimens including total body irradiation (TBI) or cyclophosphamide can mobilize high-mobility group box 1 (HMGB1) to peripheral blood. Additionally, increased plasminogen activator inhibitor (PAI)-1 levels are associated with post-allogeneic hematopoietic stem cell transplantation (aHSCT). However, changes to circulating levels of HMGB1 after aHSCT are poorly understood. Materials and methods: The study cohort included 289 patients who underwent aHSCT at one of 25 institutions in Japan. We have investigated the relationship between HMGB1 and PAI-1 following aHSCT. A significant increase in HMGB1 levels occurred after conditioning treatment. Additionally, levels of HMGB1 at day 0 were significantly increased in TBI+ patients and cyclophosphamide/TBI patients. Conclusion: Our data revealed that an increased level of HMGB1 at day 0 following aHSCT correlates with increased PAI-1 after aHSCT, which is consistent with previous reports. Increased HMGB1 at day 0 after a conditioning regimen may play a role in transplantation-associated coagulopathy following aHSCT, because PAI-1 can accelerate procoagulant activity.

    DOI: 10.2147/JBM.S93008

    Scopus

    PubMed

    researchmap

  • A case of pancreatic neuroendocrine tumors 査読

    Moriyama Masato, Matsumoto Yoshifumi, Zhou Qiliang, Yamana Kanako, Ikeda Yohei, Ayukawa Fumio, Abe Eisuke, Sato Seijiro, Takano Kabuto, Kaidu Motoki, Aoyama Hidefumi, Saijo Yasuo

    INTERNATIONAL CANCER CONFERENCE JOURNAL   5 ( 1 )   1 - 4   2016年1月

  • Possible Involvement of Lung Cells Harboring an Abnormal Karyotype in the Pathogenesis of Pulmonary Alveolar Proteinosis Associated with Myelodysplastic Syndrome. 査読

    Moriyama M, Yano T, Furukawa T, Takada T, Ushiki T, Masuko M, Takizawa J, Sone H, Tazawa R, Saijo Y, Ishii H, Nakata K

    Annals of the American Thoracic Society   12 ( 8 )   1251 - 1253   2015年8月

  • The association of level of reduction of Wilms' tumor gene 1 mRNA transcript in bone marrow and outcome in acute myeloid leukemia patients 査読

    Yasuhiko Shibasaki, Yoshinobu Seki, Tomoyuki Tanaka, Syukuko Miyakoshi, Kyoko Fuse, Takashi Kozakai, Hironori Kobayashi, Takashi Ushiki, Takashi Abe, Toshio Yano, Masato Moriyama, Takashi Kuroha, Noriatsu Isahai, Jun Takizawa, Miwako Narita, Satoru Koyama, Tatsuo Furukawa, Hirohito Sone, Masayoshi Masuko

    LEUKEMIA RESEARCH   39 ( 6 )   667 - 671   2015年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:PERGAMON-ELSEVIER SCIENCE LTD  

    We focused on the level of reduction of Wilms' tumor gene 1 (WT1) mRNA in bone marrow as minimal residual disease during chemotherapies in adult acute myeloid leukemia (AML) patients. Forty-eight patients were enrolled in this study. Log levels of reduction of WT1 mRNA transcript after induction therapy compared with those at diagnosis were associated with disease-free survival (DFS) (P = 0.0066) and overall survival (OS) (P = 0.0074) in patients who achieved complete remission. Also log levels of reduction of WT1 mRNA transcript after final consolidation therapy compared with those at diagnosis were associated with DFS (P = 0.015) and OS (P = 0.012). By multivariate analysis, log levels of reduction of WT1 mRNA transcript after induction therapy and after final consolidation therapy compared with those at diagnosis were extracted as risk factors for outcome. Our results suggest that early and deep reduction of tumor burden may be important for the outcome of AML patients. In addition, it may be useful for the decision to proceed with allogeneic SCT as post-remission therapy. (C) 2015 Elsevier Ltd. All rights reserved.

    DOI: 10.1016/j.leukres.2015.03.021

    Web of Science

    PubMed

    researchmap

  • A case of severe thrombocytopaenia associated with acute HIV-1 infection 査読

    Ami Aoki, Hiroshi Moro, Takayuki Watanabe, Katsuaki Asakawa, Satoru Miura, Masato Moriyama, Yoshinari Tanabe, Hiroshi Kagamu, Ichiei Narita

    INTERNATIONAL JOURNAL OF STD & AIDS   26 ( 3 )   209 - 211   2015年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SAGE PUBLICATIONS LTD  

    A 23-year-old man was admitted to our hospital with severe thrombocytopaenia. He had unprotected sexual contact 6 weeks earlier. He was diagnosed with acute HIV infection by means of HIV RNA viral load testing and HIV-associated thrombocytopaenia. Although his thrombocytopaenia improved immediately with short-term dexamethasone therapy, this effect was not sustained after cessation of therapy. Antiretroviral therapy including raltegravir was initiated, and the patient recovered from severe thrombocytopaenia within several days. The findings from this case suggest that acute HIV infection should be suspected with unexplained thrombocytopaenia, and that antiretroviral therapy is the treatment of choice for severe HIV-associated thrombocytopaenia, even when in the early period following acquisition of the virus.

    DOI: 10.1177/0956462414531937

    Web of Science

    PubMed

    researchmap

  • Late Onset Post-Transfusion Hepatitis E Developing during Chemotherapy for Acute Promyelocytic Leukemia 査読

    Kyoko Fuse, Yuichi Matsuyama, Masato Moriyama, Shukuko Miyakoshi, Yasuhiko Shibasaki, Jun Takizawa, Tatsuo Furukawa, Ichiro Fuse, Hiro Matsumura, Shigeharu Uchida, Yoshifumi Takahashi, Kenya Kamimura, Hiroyuki Abe, Takeshi Suda, Yutaka Aoyagi, Hirohito Sone, Masayoshi Masuko

    INTERNAL MEDICINE   54 ( 6 )   657 - 661   2015年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:JAPAN SOC INTERNAL MEDICINE  

    We herein report the case of a leukemia patient who developed hepatitis E seven months after undergoing a transfusion with contaminated blood products. The latency period in this case was significantly longer than that of typical hepatitis E. Recently, chronic infection with hepatitis E virus (HEV) genotype 3 has been reported in immunocompromised patients. There is a possibility that our patient was unable to eliminate the virus due to immunosuppression following chemotherapy and the administration of steroids. The prevalence of HEV in healthy Japanese individuals is relatively high and constitutes a critical source of infection via transfusion. Hepatitis E is an important post-transfusion infection, and immunocompromised patients may exhibit a long latency period before developing the disease.

    DOI: 10.2169/internalmedicine.54.2332

    Web of Science

    PubMed

    researchmap

  • Log Reduction Levels of WT1 mRNA Expression in BM after Chemotherapies Are Predictive Markers of Good Prognosis in AML Patients Achieved CR after Induction Therapy 査読

    Yasuhiko Shibasaki, Yoshinobu Seki, Tomoyuki Tanaka, Syukuko Miyakoshi, Kyoko Fuse, Takashi Kozakai, Hironori Kobayashi, Takashi Ushiki, Takashi Abe, Toshio Yano, Masato Moriyama, Takashi Kuroha, Noriatsu Isahai, Jun Takizawa, Miwako Narita, Satoru Koyama, Tatsuo Furukawa, Hirohito Sone, Masayoshi Masuko

    BLOOD   124 ( 21 )   2014年12月

     詳細を見る

    記述言語:英語   出版者・発行元:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • Imaging of Body Iron Stores in Transfusion-Dependent Patients By Liver Dual-Energy CT 査読

    Hironori Kobayashi, Norihiko Yoshimura, Takashi Ushiki, Yasuhiko Shibasaki, Masato Moriyama, Jun Takizawa, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    BLOOD   124 ( 21 )   2014年12月

     詳細を見る

    記述言語:英語   出版者・発行元:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • Differentiation of Mouse Induced Pluripotent Stem Cells Into Alveolar Epithelial Cells In Vitro for Use In Vivo 査読

    Qiliang Zhou, Xulu Ye, Ruowen Sun, Yoshifumi Matsumoto, Masato Moriyama, Yoshiya Asano, Yoichi Ajioka, Yasuo Saijo

    STEM CELLS TRANSLATIONAL MEDICINE   3 ( 6 )   675 - 685   2014年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ALPHAMED PRESS  

    Alveolar epithelial cells (AECs) differentiated from induced pluripotent stem cells (iPSCs) represent new opportunities in lung tissue engineering and cell therapy. In this study, we modified a two-step protocol for embryonic stem cells that resulted in a yield of similar to 9% surfactant protein C (SPC)(+) alveolar epithelial type II (AEC II) cells from mouse iPSCs in a 12-day period. The differentiated iPSCs showed morphological characteristics similar to those of AEC II cells. When differentiated iPSCs were seeded and cultured in a decellularized mouse lung scaffold, the cells reformed an alveolar structure and expressed SPC or T1 alpha protein (markers of AEC II or AEC I cells, respectively). Finally, the differentiated iPSCs were instilled intratracheally into a bleomycin-induced mouse acute lung injury model. The transplanted cells integrated into the lung alveolar structure and expressed SPC and T1 alpha. Significantly reduced lung inflammation and decreased collagen deposition were observed following differentiated iPSC transplantation. In conclusion, we report a simple and rapid protocol for in vitro differentiation of mouse iPSCs into AECs. Differentiated iPSCs show potential for regenerating three-dimensional alveolar lung structure and can be used to abrogate lung injury.

    DOI: 10.5966/sctm.2013-0142

    Web of Science

    PubMed

    researchmap

  • Manifestations of Fulminant CD8 T-cell Post-transplant Lymphoproliferative Disorder Following the Administration of Rituximab for Lymphadenopathy with a High Level of Epstein-Barr Virus (EBV) Replication after Allogeneic Hematopoietic Stem Cell Transplantation 査読

    Tomoyuki Tanaka, Jun Takizawa, Shukuko Miyakoshi, Takashi Kozakai, Kyoko Fuse, Yasuhiko Shibasaki, Masato Moriyama, Koichi Ohshima, Ken Toba, Tatsuo Furukawa, Hirohito Sone, Masayoshi Masuko

    INTERNAL MEDICINE   53 ( 18 )   2115 - 2119   2014年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:JAPAN SOC INTERNAL MEDICINE  

    We herein report the case of a 22-year-old woman with severe aplastic anemia who underwent allogeneic hematopoietic stem cell transplantation (HSCT). After HSCT, the Epstein-Barr virus (EBV)-DNA load in the peripheral blood gradually increased, and the patient presented with a fever and lymphadenopathy on day 56 post-HSCT. Although we administered rituximab, her clinical condition worsened. After rituximab treatment, CD8 T-cells emerged and became dominant in the peripheral blood, some of which were positive on an EBV-specific tetramer analysis. However, an open biopsy of the lymphadenopathy lesions revealed the CD8 T-cells to be infected with EBV, exhibiting proliferation with oligoclonality. The patient ultimately died of multiple organ failure on day 99 post-HSCT.

    DOI: 10.2169/internalmedicine.53.2384

    Web of Science

    PubMed

    researchmap

  • Development of a new P-T controlling system for neutron-scattering experiments 査読

    Kazuki Komatsu, Masato Moriyama, Tamami Koizumi, Kazuya Nakayama, Hiroyuki Kagi, Jun Abe, Stefanus Harjo

    HIGH PRESSURE RESEARCH   33 ( 1 )   208 - 213   2013年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:TAYLOR & FRANCIS LTD  

    We developed a new device involving an individual PT controlling system for neutron-scattering experiments available at 010GPa and at 77473K. Thanks to the thermal insulators made of zirconia and glass-fiber-reinforced plastic under the anvils, temperature only around anvils can be controllable with fast heating/cooling rate of&lt;20K/min, and it also allows us to use normal hydraulic oil even at low temperatures, which has much less risk of leaking compared with helium gas. The feasibility test for this system for neutron diffraction experiments for ice VIII shows that the full decompression is established without any technical difficulty, which used to be not straightforward by the previous systems.

    DOI: 10.1080/08957959.2012.762914

    Web of Science

    researchmap

  • Successful Treatment of Severe Newly Diagnosed Immune Thrombocytopenia Involving an Alveolar Hemorrhage with Combination Therapy Consisting of Romiplostim, Rituximab and Vincristine 査読

    Kiyoshi Okazuka, Masayoshi Masuko, Yuji Matsuo, Shukuko Miyakoshi, Tomoyuki Tanaka, Takashi Kozakai, Hironori Kobayashi, Kyoko Fuse, Yasuhiko Shibasaki, Masato Moriyama, Jun Takizawa, Ichiro Fuse, Ken Toba, Tatsuo Furukawa

    INTERNAL MEDICINE   52 ( 11 )   1239 - 1242   2013年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:JAPAN SOC INTERNAL MEDICINE  

    A 51-year-old man was admitted due to a severe bleeding tendency. After he was diagnosed with immune thrombocytopenia (ITP), several therapies, including steroids, steroid pulse, vincristine and rituximab, were administered; however, the patient's bleeding symptoms were not sufficiently controllable with these treatments. Subsequently, a diffuse alveolar hemorrhage was observed. Treatment with a thrombopoietin receptor agonist, romiplostim, was initiated to prevent lethal hemorrhaging, although the efficacy of thrombopoietic receptor agonists in such emergency situations has not been elucidated. The initiation of romiplostim achieved prompt remission in platelets. This case suggests that combination therapy with romiplostim, rituximab and vincristine is effective in cases of newly diagnosed severe therapy-resistant ITP.

    DOI: 10.2169/internalmedicine.52.0080

    Web of Science

    PubMed

    researchmap

  • A novel synthetic derivative of human erythropoietin designed to bind to glycosaminoglycans 査読

    Masato Moriyama, Ken Toba, Haruo Hanawa, Kiminori Kato, Takao Yanagawa, Tsugumi Takayama, Takuya Ozawa, Hironori Kobayashi, Masato Higuchi, Hideki Saito, Yoshifusa Aizawa

    DRUG DELIVERY   19 ( 4 )   202 - 207   2012年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:INFORMA HEALTHCARE  

    To synthesize long-acting and antiangiogenic erythropoietin to be clinically applied for treatment of patients with solid tumors, we synthesized a hybrid molecule of human erythropoietin added onto the C-terminus with a heparin-binding motif of human PLGF-2 to develop a novel derivative of long-acting and antiangiogenic erythropoietin: heparin-binding erythropoietin (HEPO), and studied the characteristics of this novel erythropoietin derivative. HEPO cDNA was synthesized, expressed in insect cells, and the protein was purified using a heparin-sepharose affinity column. The erythropoietic and angiogenic effects of the partially purified protein were analyzed in vitro and in vivo. The erythropoietic activity of the protein was equivalent to natural EPO in vitro. In vivo administration of the protein to mice revealed its long-acting erythropoietic activity as expected. Administration of the protein inhibited angiogenesis in a mouse limb ischemia model. In conclusion, the heparin-binding motif of PLGF-2 may act as, so to speak, a superendostatin. This novel long-acting erythropoietin derivative may have an advantage to inhibit tumor growth while preserving hematopoietic and tissue-protective effects.

    DOI: 10.3109/10717544.2012.690004

    Web of Science

    PubMed

    researchmap

  • Myelodysplastic Syndrome with Ph Negative Monosomy 7 Chromosome following Transient Bone Marrow Dysplasia during Imatinib Treatment for Chronic Myeloid Leukemia 査読

    Kaori Karimata, Masayoshi Masuko, Takashi Ushiki, Takashi Kozakai, Yasuhiko Shibasaki, Toshio Yano, Takashi Abe, Masato Moriyama, Ken Toba, Tatsuo Furukawa, Yoshifusa Aizawa

    INTERNAL MEDICINE   50 ( 5 )   481 - 485   2011年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:JAPAN SOC INTERNAL MEDICINE  

    We describe a 60-year-old Japanese patient with chronic myeloid leukemia (CML) who developed myelodysplastic syndrome (MDS) with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment. Most cases that developed chromosomal abnormality in Ph negative cells during imatinib therapy were reported to have less clinical implications, while rare cases developed MDS/AML. The present case suggested that metaphase karyotype analysis and bone marrow examination should be performed for the long term follow-up under imatinib treatment in cases showing cytopenia. The results also suggested that monosomy 7 in Ph negative cells may be an indicator of a poor prognosis.

    DOI: 10.2169/internalmedicine.50.4481

    Web of Science

    PubMed

    researchmap

  • Pharmacokinetic and pharmacodynamic analysis of cyclosporine A (CsA) to find the best single time point for the monitoring and adjusting of CsA dose using twice-daily 3-h intravenous infusions in allogeneic hematopoietic stem cell transplantation 査読

    Tatsuo Furukawa, Tori Kurasaki-Ida, Masayoshi Masuko, Nobuhiro Tsukada, Kiyoshi Okazuka, Naoko Sato, Toshio Yano, Takashi Abe, Akihito Momoi, Yasuhiko Shibasaki, Masutaka Higashimura, Kaori Karimata, Masato Moriyama, Takashi Kuroha, Jun Takizawa, Ken Toba, Miwako Narita, Ichiro Fuse, Masuhiro Takahashi, Yoshifusa Aizawa

    INTERNATIONAL JOURNAL OF HEMATOLOGY   92 ( 1 )   144 - 151   2010年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER TOKYO  

    Pharmacological study is predictably effective in establishing an optimal monitoring strategy for the usage of cyclosporine A (CsA) to prevent graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation recipients. Pharmacokinetic profiling of 33 recipients administered CsA twice daily by 3-h intravenous infusion revealed that levels peaked 2-3 h after the start of infusion, and an exponential decline of CsA concentrations after the termination of infusion was observed. The correlation between the area under the curve (AUC(0-12)) and CsA concentration at various time points after infusion revealed that C (2) and C (3) correlated best with AUC(0-12) (r (2) = 0.725), while the trough concentration correlated poorly. Ex vivo T cell stimulation followed by intracellular cytokine detection with flow cytometry revealed that the capacity of T cells to produce cytokines upon stimulation was inversely proportional to the CsA concentration, and reached a minimum at about 700 ng/mL with a marginal decrease above this concentration. Extrapolation using the regression equations of this study and the data from our retrospective study leads to the assumption that the dose adjustment of CsA based on maintaining the C (3) concentration above 800 ng/mL may effectively prevent acute GVHD. To confirm this assumption, a prospective clinical study is required.

    DOI: 10.1007/s12185-010-0610-0

    Web of Science

    PubMed

    researchmap

  • Serum erythropoietin level as a marker of limb ischemia 査読

    Takuya Ozawa, Kiminori Kato, Ken Toba, Masato Oda, Manabu Isoda, Fuyuki Asami, Noboru Ikarashi, Takao Yanagawa, Masato Moriyama, Masutaka Higashimura, Toshiki Kitajima, Keita Otaki, Tsugumi Takayama, Satoru Hirono, Yuji Okura, Haruo Hanawa, Makoto Kodama, Yoshifusa Aizawa

    INTERNATIONAL JOURNAL OF CARDIOLOGY   130 ( 1 )   106 - 108   2008年10月

     詳細を見る

    記述言語:英語   出版者・発行元:ELSEVIER IRELAND LTD  

    Bone marrow implantation (BMI) has been utilized for the treatment of limb ischemia, however, serum markers have not yet been reported to express the degree of limb ischemia. We analyzed the serum levels of several cytokines including erythropoietin (EPO) in the treated legs and the contralateral ones in 11 patients with limb ischemia treated with BMI. The EPO level in the pre-treated legs in the 5 patients with arteriosclerosis obliterans revealed a good correlation with ankle-brachial pressure index. The EPO level, but not the levels of TNF-alpha, VEGF, and bFGF in the pre-treated legs was significantly higher than that in the contralateral legs in the 11 patients, and the EPO level decreased in 4 weeks after BMI. The serum EPO level may express the degree of limb ischemia presumably through the reactive production of EPO in ischemic tissue. (C) 2007 Elsevier Ireland Ltd. All rights reserved.

    DOI: 10.1016/j.ijcard.2007.07.005

    Web of Science

    PubMed

    researchmap

  • Imatinib mesilate inhibits neointimal hyperplasia via growth inhibition of vascular smooth muscle cells in a rat model of balloon injury 査読

    Yashiro Makiyama, Ken Toba, Kiminori Kato, Satoru Hirono, Takuya Ozawa, Takashi Saigawa, Shiro Minagawa, Manabu Isoda, Fuyuki Asami, Noboru Ikarashi, Masato Oda, Masato Moriyama, Masutaka Higashimura, Toshki Kitajinia, Keita Otaki, Yoshifusa Aizawa

    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE   215 ( 4 )   299 - 306   2008年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:TOHOKU UNIV MEDICAL PRESS  

    Restenosis is a major problem in percutaneous catheter intervension (PCT) for coronary artery stenosis in patients with acute myocardial infarction. Coronary restenosis arises from intimal hyperplasia, i.e., hyperplasia of the vascular smooth muscle cells (SMCs) caused by endothelial cell (EC) damage due to PCT. Drug eluting stent (DES), a novel stent coated with a cell-growth inhibitor, such as rapamycin, has been utilized to block SMC proliferation, but DES also blocks EC repair and thus requires the administration of anti-platelets for a lone, time to prevent thrombus formation after PCT. Moreover, insufficient prevention of platelet aggregation sometimes induces restenosis after PCT. One of the signal transduction inhibitors, imatinib mesilate, blocks tyrosine kinase activity of platelet-derived growth factor receptor (PDGFR), and therefore it may block the development of neointima through growth inhibition of SMCs without the obstructive effect on EC-repair. We therefore studied the effects of imatinib on neointimal hyperplasia in a balloon injury model of rat carotid arteries. Rats were orally administered with imatinib for 14 days after balloon injury, and sacrificed to analyze the neointimal formation. Intimal hyperplasia was inhibited by imatinib in a dose-dependent manner. Therefore imatinib presumably obstructed the growth of SMCs via interception on growth-signaling of PDGFR. The administration of imatinib after coronary stenting or the use of an imatinib-eluting stent may further reduce the risk of restenosis in patients.

    DOI: 10.1620/tjem.215.299

    Web of Science

    PubMed

    researchmap

  • Prognostic factors of critical limb ischemia after autologous bone marrow implantation 査読

    Masato Oda, Kiminori Kato, Ken Toba, Keita Otaki, Toshiki Kitajima, Noboru Ikarashi, Takao Yanagawa, Masutaka Higashimura, Fuyuki Asami, Manabu Isoda, Takuya Ozawa, Masato Moriyama, Satoru Hirono, Yuji Okura, Haruo Hanawa, Makoto Kodama, Yoshifusa Aizawa

    Journal of Cardiology   50 ( 4 )   235 - 242   2007年

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    Objectives. Autologous bone marrow implantation (BMI) is effective to treat critical limb ischemia, but the long-term prognosis is not clear. The outcome of BMI treatment for ischemic legs was investigated related to the clinical background of the patient, and short-term effects of BMI. The end event was defined as unexpected lower limb amputation. Methods and Results. This study included 21 consecutive patients (mean age 60.0 ± 13.6 years) with peripheral arterial disease who underwent BMI between December 2001 and March 2005. Twelve patients had arteriosclerosis obliterans (ASO), 5 had Buerger disease (thromboangiitis obliterans), 3 had thromboembolism, and 1 had hypereosinophilic syndrome. The patients with ASO had severe complications such as diabetes and hyperlipidemia. The total number of transplanted CD34-positive cells, ankle-brachial pressure index (ABI), and tissue oxygen pressure (TcO 2) were lower in ASO patients than non-ASO patients. Significant risk factors for the event were diagnosis of ASO and low TcO2 (&lt
    30 mmHg) according to the Kaplan-Meier survival curve and log rank test. All 6 patients who required limb amputation had ASO simultaneously with low TcO 2 (6 of 9, 67%). In contrast, there was no correlation between the end event and short-term effect of BMI such as improvements in ABI and TcO 2. Conclusions. Treatment with BMI could not save legs in some patients with ASO associated with severe leg ischemia.

    Scopus

    PubMed

    researchmap

  • Erythroid cells play essential roles in angiogenesis by bone marrow cell implantation 査読

    Takuya Ozawa, Ken Toba, Kiminori Kato, Shiro Minagawa, Takashi Saigawa, Haruo Hanawa, Yashiro Makiyama, Masato Moriyama, Kei-ichiro Honma, Manabu Isoda, Go Hasegawa, Makoto Naito, Masuhiro Takahashi, Yoshifusa Aizawa

    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY   40 ( 5 )   629 - 638   2006年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD  

    Bone marrow cell implantation (BMI) has been utilized to treat patients with limb and heart ischemia. BMI provides angiogenic precursors and angiogenic cytokine-producing cells, especially erythroid cells. In this study, we induced in vitro angiogenesis cultures and in vivo BMI simulation using a marine limb ischemia model to examine the role of erythroid cells and the effect of erythropoietin (EPO). Human erythroid colonies (BFU-e) induced capillary networks around the colonies in vitro. Erythroid cells in human bone marrow produced vascular endothelial growth factor and placental growth factor. The angiogenic effects of erythroid cells were further amplified in the presence of EPO. Limb-ischemic mice were treated with BMI +/- EPO, and limb survival, blood flow recovery, and muscle histology were analyzed. Treatment with whole bone marrow cells + EPO significantly improved limb survival and blood flow. The cumulative effects of EPO on BMI induced and increase in capillary number and artery enlargement. Erythroid cells were essential for the in vivo effects of BMI, and CD14-positive cells supported the biological effects. In addition to the direct effect of EPO on angiogenesis, EPO showed indirect effect on angiogenesis through amplifying the angiogenic effects by erythroid cells supported by CD14-positive cells. (c) 2006 Elsevier Ltd. All rights reserved.

    DOI: 10.1016/j.yjmcc.2006.01.023

    Web of Science

    PubMed

    researchmap

  • Masked MLL gene rearrangement was disclosed in the clinical course and sequential development of chromosome abnormality in a patient with therapy related acute myelogeneous leukemia 査読

    S Hashimoto, K Toba, N Izumi, N Sato, H Takahashi, T Ozawa, M Moriyama, S Aoki, T Furukawa, M Narita, M Takahashi, Y Aizawa

    LEUKEMIA RESEARCH   27 ( 3 )   285 - 290   2003年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:PERGAMON-ELSEVIER SCIENCE LTD  

    Therapy related acute myelogenous leukemia in a 55-year-old Japanese woman is described. She had been treated for a diagnosis of non-Hodgkin's lymphoma 2 years before the onset of the secondary leukemia. She was diagnosed as AML (FAB: M2) with monosomy 7, and successfully treated by an intensive combination chemotherapy followed by an autologous peripheral blood stem cell transplantation. The disease relapsed shortly after the treatment, and the karyotype analysis revealed a complex abnormality accompanied with t(9; 11)(p22;q23), however, monosomy 7 was absent. Southern blotting analysis was performed, and MLL rearrangement was evident in both the bone marrow samples obtained at that time and the cryopreserved marrow cells obtained at the onset of the disease. The bone marrow sample stored in a Camoy solution at the onset was further analyzed, and three karyotype panels showing 45,XX, -7, t(9;11)(p22;q23) were found. Like this situation, a masked MLL rearrangement may have existed in some cases with hematopoictic malignancies, and appear to be disclosed in the clinical course. (C) 2002 Elsevier Science Ltd. All rights reserved.

    DOI: 10.1016/S0145-2126(02)00176-5

    Web of Science

    PubMed

    researchmap

▶ 全件表示

書籍等出版物

  • 血栓形成の最初期段階における病態機序の解明とvon Willebrand因子(VWF)関連検査の有用性の検討

    森山雅人( 担当: 単著)

    新潟県医師会報  2014年11月 

     詳細を見る

  • 肺がんにj対する抗体療法

    森山雅人( 担当: 単著)

    最新医学  2014年3月 

     詳細を見る

  • Heparin-Binding Erythropoietin. Frontiers in Drug Discovery,Ken Toba and Masato Moriyama,Erythropoietic Stimulating Agents

    森山雅人( 担当: 共著)

    2013年10月 

     詳細を見る

  • 高齢者のde novo急性白血病の治療

    森山雅人( 担当: 単著)

    科学評論社  2011年6月 

     詳細を見る

  • 大学病院連携型高度医療人養成推進事業「NAR大学・地域-連携『+α専門医』の養成」プログラム

    森山雅人( 担当: 共著)

    新潟医学会雑誌  2010年10月 

     詳細を見る

  • ヘパリン結合性エリスロポエチンの作成とその生物学的特性の検討

    森山雅人( 担当: 単著)

    新潟医学会雑誌  2008年7月 

     詳細を見る

▶ 全件表示

MISC

▶ 全件表示

講演・口頭発表等

  • がん治療と支持療法〜発熱性好中球減少症管理の重要性〜

    森山雅人

    浜松市医師会 がん治療フォーラム  2019年  浜松市医師会

     詳細を見る

    開催地:浜松市  

    researchmap

  • がんと静脈血栓塞栓症

    森山雅人

    室蘭市医師会学術講演会  2019年  室蘭市医師会

     詳細を見る

    開催地:室蘭市  

    researchmap

  • がんと血栓塞栓症

    森山雅人

    鶴岡地区医師会消化器病懇話会  2018年  鶴岡地区医師会

     詳細を見る

    開催地:鶴岡市  

    researchmap

  • がん口腔支持療法への期待

    森山雅人

    日本がん口腔支持療法学会 第4回学術大会  2018年  日本がん口腔支持療法学会

     詳細を見る

    開催地:新潟市  

    researchmap

  • 頭頸部がんの化学療法

    森山雅人

    第36回日本口腔腫瘍学会総会・学術集会  2018年  日本口腔腫瘍学会

     詳細を見る

    開催地:新潟市  

    researchmap

  • Cardio-Oncology Seminar 2018 〜がんと血栓塞栓症〜

    森山雅人

    上越医師会講演会  2018年  上越医師会

     詳細を見る

    開催地:上越市  

    researchmap

  • がんと血栓塞栓症

    森山雅人

    第728回新潟医学会  2017年  新潟大学

     詳細を見る

    開催地:新潟市  

    researchmap

  • Clinical Decision Making に有用な血栓止血系検査の話題〜血友病からがんと血栓塞栓症まで〜

    森山雅人

    第39回日本血栓止血学会学術集会  2017年  日本血栓止血学会

     詳細を見る

    開催地:名古屋市  

    researchmap

  • がんと血栓症

    森山雅人

    日本臨床腫瘍学会 第8回北信越地区セミナー  2017年  日本臨床腫瘍学会

     詳細を見る

    開催地:上越市  

    researchmap

  • 静脈血栓塞栓症の現状と治療

    森山雅人

    須高医師会学術講演会  2017年  須高医師会

     詳細を見る

    開催地:須坂市  

    researchmap

▶ 全件表示

産業財産権

受賞

  • 学術研究助成

    新潟県医師会   血栓形成の最初期段階における病態機序の解明とvon Willebrand因子(VWF)関連検査の有用性の検討

    森山雅人

     詳細を見る

共同研究・競争的資金等の研究

  • 直接経口抗凝固薬(DOAC)に対する血中モニタリング法の開発

    研究課題/領域番号:20K07842  2020年4月 - 2023年3月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    森山 雅人

      詳細を見る

    配分額:4290000円 ( 直接経費:3300000円 、 間接経費:990000円 )

    researchmap

  • ヘパリン親和性エリスロポエチンの組織保護・再生効果の検討

    2016年4月 - 2019年3月

    文部科学省  科研費 

    森山雅人

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • 体外増幅自己赤芽球移植と自己骨髄単核細胞移植による血管新生治療の比較試験

    2015年4月 - 2018年3月

    文部科学省  科研費 

    小澤拓也

      詳細を見る

    資金種別:競争的資金

    researchmap

  • 血栓形成の最初期段階における病態機序の解明とvon Willebrand因子関連検査の有用性の検討

    2014年4月 - 2015年3月

    新潟県医師会  研究助成金 

    森山雅人

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • ヘパリン親和性エリスロポエチン発現系の確立と生物学的特性の検討

    2013年4月 - 2016年3月

    文部科学省  科研費 

    森山雅人

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • 体外増幅赤芽球移植を用いた血管新生治療の長期予後と治療効果の予測因子の検討

    2012年4月 - 2015年3月

    文部科学省  科研費 

    小澤拓也

      詳細を見る

    資金種別:競争的資金

    researchmap

▶ 全件表示

 

担当経験のある授業科目

  • 血液系

    2011年
    -
    現在
    機関名:新潟大学